Our mission is to make progress toward racial equity in clinical research
Let's make a difference for Underrepresented Patients
Advancing Health Equity
At Exelixis, we recognize that many racial and ethnic communities are underrepresented in clinical research. Inclusive clinical trial design improves the quality and equity of treatments for key affected populations. Exelixis is dedicated to identifying, discussing, and implementing solutions that will increase the number of patients from underrepresented populations in all phases of clinical trials supported and sponsored by the company.
CURRENT STATE OF HEALTH EQUITY
Oncology clinical trials in the U.S. do not reflect the diversity in our communities. In recent clinical studies that led to FDA oncology approvals (2008-2018), 76.3% of participants were White, 18.3% of participants were Asian, 6.1% were Hispanic, and 3.1% were Black.1 As a comparison, the U.S. population in 2021 was estimated to be 59.3% White, 6.1% Asian, 18.9% Hispanic, and 13.6% Black.2 Increasing the number of people from diverse backgrounds (e.g., age, race, ethnicity, low income) in clinical trials is key to advancing health equity.3,4
Cancer Clinical Trials Underrepresent
Certain U.S. Populations
HEALTH EQUITY IN PROSTATE CANCER
Improving representation among marginalized groups is especially important for men with prostate cancer, a group in which the disparity is evident. Clinical trial enrollment for patients with prostate cancer does not accurately reflect the incidence of prostate cancer by race.1,6
Disproportionate Prostate Cancer
Incidence, Mortality, and Clinical
Worse Mortality for
START THE CONVERSATION
Consider discussing clinical trials with your patients during their next visit.
Research shows that more than half of all cancer patients, regardless of race, will agree to participate in a clinical trial if their healthcare provider offers it to them.5
Consider asking your patients living with mCRPC* if they are interested in learning more about the CONTACT-02 clinical trial.
*Metastatic castration-resistant prostate cancer.